Clarus Therapeutics Holdings, Inc. (CRXT): Price and Financial Metrics

Clarus Therapeutics Holdings, Inc. (CRXT): $0.42

0.04 (+11.57%)

POWR Rating

Component Grades













CRXT Stock Price Chart Interactive Chart >

Price chart for CRXT

CRXT Price/Volume Stats

Current price $0.42 52-week high $31.24
Prev. close $0.38 52-week low $0.33
Day low $0.37 Volume 5,585,100
Day high $0.45 Avg. volume 8,393,801
50-day MA $0.98 Dividend yield N/A
200-day MA $3.34 Market Cap 10.48M

Clarus Therapeutics Holdings, Inc. (CRXT) Company Bio

Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

CRXT Latest News Stream

Event/Time News Detail
Loading, please wait...

CRXT Latest Social Stream

Loading social stream, please wait...

View Full CRXT Social Stream

Latest CRXT News From Around the Web

Below are the latest news stories about Clarus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate CRXT as an investment opportunity.

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients

JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions New offerings underscore Clarus’ continued commitment to providing solutions for patients Partnership with Vault Health enables clinical care from the comfort of patients’ homes Partnership with AssistRx, the intelligent therapy initiation and patient support solutions provider, streamlines process for JATENZO prescr

Yahoo | February 24, 2022

Maxim Group Thinks Clarus Therapeutics Holdings’ Stock is Going to Recover

In a report issued on February 2, Naz Rahman from Maxim Group maintained a Buy rating on Clarus Therapeutics Holdings (CRXT – Research Report), with a price target of $4.00. The company's shares closed last Friday at $1.28, close to its 52-week low of $1.16. According to, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.8% and a 4.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Galmed Pharmaceuticals, and Quoin Pharmaceuticals. Currently, the analyst consensus on Clarus Therapeutics Holdings is a Moderate Buy with an average price target of $8.00.

Howard Kim on TipRanks | February 6, 2022

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical

Yahoo | January 18, 2022

Powell Investment Advisors, LLC Buys SVF Investment Corp, Meta Platforms Inc, Vanguard Large ...

Investment company Powell Investment Advisors, LLC (Current Portfolio) buys SVF Investment Corp, Meta Platforms Inc, Vanguard Large Cap ETF, Bank of America Corp, Eli Lilly and Co, sells Financial Select Sector SPDR, ARK Innovation ETF, Unilever PLC, AMMO Inc, Apollo Global Management Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Powell Investment Advisors, LLC.

Yahoo | January 15, 2022

Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement

Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has closed its previously announced definitive agreement to sell securities in a private placement with a leading healthcare inves

Yahoo | December 7, 2021

Read More 'CRXT' Stories Here

CRXT Price Returns

1-mo -43.24%
3-mo -55.41%
6-mo -91.94%
1-year -95.82%
3-year N/A
5-year N/A
YTD -82.72%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5906 seconds.